Clinical Trial: Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07441408) titled 'Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis' on Feb. 25.

Brief Summary: The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

Study Start Date: Dec. 16, 2026

Study Type: INTERVENTIONAL

Condition: Pulmonary Fibrosis

Intervention: DRUG: BMS-986278

Specified dose on specified days

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Bristol-Myers Squi...